Trade Pluri Inc. - PLUR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.2660 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02354% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001318% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.257 |
| Open | 4.337 |
| 1-Year Change | 401.45% |
| Day's Range | 4.187 - 4.337 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 28, 2025 | 4.1870 | -0.1500 | -3.46% | 4.3370 | 4.3370 | 4.1870 |
| Mar 27, 2025 | 4.2570 | 0.0700 | 1.67% | 4.1870 | 4.2670 | 4.1870 |
| Mar 26, 2025 | 4.2670 | -0.0200 | -0.47% | 4.2870 | 4.2870 | 4.1470 |
| Mar 25, 2025 | 4.2570 | 0.0400 | 0.95% | 4.2170 | 4.2570 | 4.0470 |
| Mar 24, 2025 | 4.3270 | 0.0300 | 0.70% | 4.2970 | 4.3270 | 4.2970 |
| Mar 21, 2025 | 4.1870 | 0.0400 | 0.96% | 4.1470 | 4.2170 | 3.9770 |
| Mar 20, 2025 | 4.3070 | 0.1400 | 3.36% | 4.1670 | 4.3770 | 3.9970 |
| Mar 19, 2025 | 4.2470 | 0.0200 | 0.47% | 4.2270 | 4.2970 | 4.0570 |
| Mar 18, 2025 | 4.2170 | -0.3700 | -8.07% | 4.5870 | 4.5970 | 4.1370 |
| Mar 17, 2025 | 4.5870 | 0.0000 | 0.00% | 4.5870 | 4.6070 | 4.5770 |
| Mar 14, 2025 | 4.4570 | -0.0900 | -1.98% | 4.5470 | 4.5470 | 4.4570 |
| Mar 13, 2025 | 4.3870 | -0.1800 | -3.94% | 4.5670 | 4.5970 | 4.3870 |
| Mar 12, 2025 | 4.4470 | -0.1000 | -2.20% | 4.5470 | 4.5470 | 4.3570 |
| Mar 11, 2025 | 4.3570 | -0.1900 | -4.18% | 4.5470 | 4.5870 | 4.3570 |
| Mar 10, 2025 | 4.5370 | -0.0400 | -0.87% | 4.5770 | 4.5870 | 4.3870 |
| Mar 7, 2025 | 4.5570 | 0.0700 | 1.56% | 4.4870 | 4.6870 | 4.3570 |
| Mar 6, 2025 | 4.5470 | -0.0600 | -1.30% | 4.6070 | 4.7470 | 4.3570 |
| Mar 5, 2025 | 4.5170 | 0.0400 | 0.89% | 4.4770 | 4.6970 | 4.1870 |
| Mar 4, 2025 | 4.3470 | -0.1000 | -2.25% | 4.4470 | 4.4470 | 4.1470 |
| Mar 3, 2025 | 4.4270 | -0.0200 | -0.45% | 4.4470 | 4.5070 | 4.4270 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Pluri Inc. Company profile
About Pluristem Therapeutics Inc.
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
Financial summary
BRIEF: For the six months ended 31 December 2021, Pluristem Therapeutics Inc. revenues was not reported. Net loss increased 6% to $22.4M. Higher net loss reflects General and administrative expenses increase of 30% to $4.8M (expense), Stock-based Compensation in SGA increase of 9% to $4.6M (expense), Research & Development Expense decrease of 75% to $72K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.82 to -$0.70.
Equity composition
Common Stock $0.00001 Par, 01/13, 100M auth., 58,333,206 issd. Insiders control 11.74%. IPO: NA. 11/07,1-for-200 reverse stock split. 11/07, Name changed from Pluristem Life Systems, Inc. 12/07, Exchanged changed from OTC Bulletin Board to NASDAQ.
| Industry: | Biotechnology & Medical Research (NEC) |
Matam Park Building 5
HAIFA
3508409
IL
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com